Please assess the completion status of the following clinical trial:

Trial Title: Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Over age 18 at study entry.~* Male, or female, if female, meets all of the following criteria:~* Not breastfeeding~* Post-menopausal or negative pregnancy test result (human chorionic gonadotropin, beta subunit \[β- hCG\]) at Screening (Visit 1) (not required for hysterectomized females)~* If of childbearing potential and sexually active, must practice and be willing to continue to practice appropriate birth control~* Is diagnosed with type 2 diabetes mellitus and either not adequately controlled by: diet and exercise alone or diet and exercise plus a single, first line treatment for type 2 diabetes.~* If treated with an oral anti-diabetes agent, be willing and able to withdraw from therapy for 4 weeks after the screening visit and prior to initiating study mediation at Baseline (Day 1/Visit 4).~* Be willing to avoid acetaminophen use for intervals up to 10 days as required for study procedures (see Section 4.6)~* Has a fasting plasma glucose ≥126 mg/dL to ≤220 mg/dL at Screening~* Has an HbA1c ≥7% to ≤8.5% at Screening~* Has a BMI ≤40 kg/m2~* Clinical laboratory tests (hematology, clinical chemistry, and urinalysis) either normal or abnormal but consistent with type 2 diabetes mellitus.~* Is able to read, understand, and sign the informed consent forms (ICF) and if applicable, an authorization to use and disclose protected health information form (consistent with health insurance portability and accountability act of 1996 \[HIPAA\] legislation), communicate with the investigator, and understand and comply with protocol requirements.~Exclusion Criteria:~* Clinically significant renal dysfunction~* If using any of the following medications, has not been on a stable treatment regimen for a minimum of 4 weeks prior to screening:~Lipid-lowering agents Anti-hypertensive medications Thyroid replacement therapy Non-steroidal anti-inflammatory agents~* Unable to perform self-blood glucose monitoring employing a glucose meter.~* History of active cardio- or cerebro-vascular disease with an event within the previous 6 months~* Gastrointestinal disorders~* Endocrine disorders other than type 2 diabetes~* Chronic infection~* Hepatic disease~* Neurological or psychiatric diseases~* History of other psychiatric disorders~* Has been treated (within the last month), is currently treated, or is expected to require or undergo treatment with; any anti-diabetes medications (other than as allowed by the inclusion criteria), oral or parenteral steroids.~* Participation in a weight loss program within the past 3 months.~* Weight change by more than 10 pounds during the past month.~* History of alcohol or substance abuse in the past 3 months or a positive screen for alcohol or drugs of abuse at screening.~* Has received any investigational drug within 3 months of Screening.~* Has donated blood within 3 months before Screening or is planning to donate blood during the study.~* Has known allergies or hypersensitivity to metformin or leucine~* Is employed, contracted or has an immediate family member directly affiliated with NuSirt Biopharma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Metformin (Type: EXPERIMENTAL): 3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
- Mid Metformin (Type: EXPERIMENTAL): 3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
- High Metformin (Type: EXPERIMENTAL): 3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
- Metformin Monotherapy (Type: EXPERIMENTAL): 3 Capsules BID each containing 166.7 mg of metformin with dose escalation to 283.3 mg capsules BID (1,700 mg/Day) at Day 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).